Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The evidence of transcatheter arterial chemoembolization (TACE) plus tyrosine kinase inhibitor and immune checkpoint inhibitor in unresectable hepatocellular carcinoma (HCC) was limited. This study aimed to evaluate the role of TACE plus apatinib (TACE + A) and TACE combined with apatinib plus camrelizumab (TACE + AC) in patients with unresectable HCC.
Methods: This study retrospectively reviewed patients with unresectable HCC who received TACE + A or TACE + AC in 20 centers of China from January 1, 2019 to June 31, 2021. Propensity score matching (PSM) at 1:1 was performed to reduce bias. Treatment-related adverse events (TRAEs), overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and disease control rate (DCR) were collected.
Results: A total of 960 eligible patients with HCC were included in the final analysis. After PSM, there were 449 patients in each group, and the baseline characteristics were balanced between two groups. At data cutoff, the median follow-up time was 16.3 (range: 11.9-21.4) months. After PSM, the TACE + AC group showed longer median OS (24.5 vs 18.0 months, p < 0.001) and PFS (10.8 vs 7.7 months, p < 0.001) than the TACE + A group; the ORR (49.9% vs 42.5%, p = 0.002) and DCR (88.4% vs 84.0%, p = 0.003) of the TACE + AC group were also higher than those in the TACE + A group. Fever, pain, hypertension and hand-foot syndrome were the more common TRAEs in two groups.
Conclusions: Both TACE plus apatinib and TACE combined with apatinib plus camrelizumab were feasible in patients with unresectable HCC, with manageable safety profiles. Moreover, TACE combined with apatinib plus camrelizumab showed additional benefit.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386927 | PMC |
| http://dx.doi.org/10.1007/s12072-023-10519-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Plug-based vascular closure device in transfemoral transcatheter aortic valve implantation.
J Invasive Cardiol
September 2025
Cardiac Surgery Unit, Mediterranea Cardiocentro, Naples, Italy.
Objectives: Failure of vascular closure device (VCD) is the most common cause of access-site vascular complications in transfemoral transcatheter aortic valve implantation (TAVI). The authors sought to determine if the systematic use of arteriotomy-site ballooning with concomitant manual compression following the delivery of a plug-based VCD (MANTA, Teleflex) can optimize toggle-plug assembly apposition to the common femoral artery (CFA) wall and improve the final hemostatic efficacy.
Methods: In this prospective, observational, single-center study, 323 consecutive patients undergoing transfemoral TAVI from October 2021 to December 2024 underwent access closure with the MANTA VCD.
Right coronary artery takeoff plane and implications for brachiocephalic interventions and next generation transcatheter aortic valve intervention embolic protection devices.
J Invasive Cardiol
September 2025
Newark Beth Israel Medical Center, Newark, New Jersey.
Objectives: The authors hypothesized that the origin of the right coronary artery (RCA) is a direct continuation of the major aortic arch branches (MAAB) takeoff plane, which may have implications for brachiocephalic interventions and next generation transcatheter aortic valve intervention (TAVI) embolic protection devices (EPDs).
Methods: In this single-center, retrospective, cross-sectional study, the authors analyzed computed tomographic angiography (CTA) images from 92 patients undergoing TAVI evaluation to determine the spatial relationship between the origin of the RCA and the MAAB takeoff plane. Patients with prior cardiothoracic or aortic interventions and those with anomalous RCA origin were excluded.
Durable Long-Term Outcomes After Early Transcatheter Arterialization of the Deep Veins.
JACC Case Rep
September 2025
University Hospitals Harrington Heart & Vascular Institute, Cleveland, Ohio, USA. Electronic address:
Background: Up to 20% of patients with chronic limb-threatening ischemia (CLTI) are not eligible for conventional revascularization options despite having severe symptoms of nonhealing ulcers and gangrene. Transcatheter arterialization of the deep veins (TADV) has shown promising results in this challenging subset of patients.
Case Summary: We present the long-term outcomes of 4 patients with no-option CLTI who were at risk of major below-the-knee amputation and were treated with TADV with the LimFlow System (Inari Medical).
Computational Fluid Dynamics of the Flow of the Deformable Toroidal Embolic Agents Within Straight and Stenotic Pipes by Full Eulerian FSI Method.
Int J Numer Method Biomed Eng
September 2025
Department of Chemical System Engineering, School of Engineering, The University of Tokyo, Tokyo, Japan.
The effect of shape and size of embolic agents on embolization phenomena has been discussed clinically for transcatheter arterial chemoembolization (TACE). We numerically discussed the unique embolization behavior of new deformable toroidal microparticles in blood vessels by computational fluid dynamics simulations. We employed an Eulerian-Eulerian (full Eulerian) fluid-structure interaction (FSI) method to analyze the flow and deformation behaviors of a deformable torus in a cylindrical pipe.
View Article and Find Full Text PDFOutcomes of Transcatheter or Surgical Treatment of Severe Aortic Stenosis in Patients With Coronary Artery Disease.
Struct Heart
September 2025
Heart and Vascular Institute, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
•Outcomes of surgical aortic valve replacement + coronary artery bypass grafting vs. transcatheter aortic valve replacement (TAVR) + percutaneous coronary intervention (PCI) in severe aortic stenosis and coronary artery disease patients.•TAVR + PCI had lower 30-day acute kidney injury and bleeding, similar 2-year mortality/stroke.
View Article and Find Full Text PDF